Shire Plc.’s (Shire) 3Q 08 revenues were supported by strong demand for high margin Specialty Pharmaceuticals and Human Genetic Therapies (HGT) products, in line with our expectations. However, margins exceeded our expectations, primarily due to lower-than-expected Research and Development (R&D) costs. The increasing demand and wider acceptance of Vyvanse and Elaprase should continue to support revenues in FY 2008 and FY 2009. Furthermore, Shire plans to launch Firazyr for the treatment of He